Tags

, , , , , , ,

Carpizo smaller

Dr. Darren Carpizo (Photo by Jody Somers)

BioMotiv, a drug-development accelerator associated with The Harrington Project, has created a new biotechnology startup company, Z53 Therapeutics, to discover and develop new agents for the treatment of p53-dependent cancers using a technology from Rutgers University. The company has licensed intellectual property that originated in the laboratory of Darren Carpizo, M.D., Ph.D., at Rutgers Cancer Institute of New Jersey with the discovery that small molecules can act as zinc metallochaperones to shuttle zinc across cell membranes and reactivate mutant p53. As part of his drug discovery research, Carpizo established collaborations with scientists from Rutgers Translational Sciences and in the lab of Stewart Loh, Ph.D., at SUNY Upstate Medical University.

Read the full story here.

Advertisements